Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 4, 2013, Pages 1664-1671

  Würthwein, Gudrun ^a   Cornely, Oliver A ^b,c   Trame, Mirjam N ^a,d   Vehreschild, Janne J ^c   Vehreschild, Maria J G T ^c   Farowski, Fedja ^c   Müller, Carsten ^e   Boos, Joachim ^a   Hempel, Georg ^a,d   Hallek, Michael ^c   Groll, Andreas H ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CASPOFUNGIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; FEMALE; GEOMETRY; HUMAN; INVASIVE ASPERGILLOSIS; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STEADY STATE; TANDEM MASS SPECTROMETRY;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; ASPERGILLOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHINOCANDINS; FEMALE; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84875133113     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01912-12     Document Type: Article

References (36)

1. Groll AH, Walsh TJ. 2001. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin. Invest. Drugs 10:1545-1558.
2. Ullmann AJ. 2003. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr. Med. Res. Opin. 19:263-271.
3. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. 2002. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob. Agents Chemother. 46:451-457.
4. Petraitiene R, Petraitis V, Groll AH, Sein T, Schaufele RL, Francesconi A, Bacher J, Avila NA, Walsh TJ. 2002. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob. Agents Chemother. 46: 12-23.
5. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. 2001. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin. Infect. Dis. 33:1529-1535.
6. Keizer RJ, van Benten M, Beijnen JH, Schellens JHM, Huitema ADR. 2011. Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM. Computer Methods Programs Biomed. 101:72-79.
7. Betts RF, Nucci M, Talwar D, Gareca M, Queiroz-Telles F, Bedimo RJ, Herbrecht R, Ruiz-Palacios G, Young JA, Baddley JW, Strohmaier KM, Tucker KA, Taylor AF, Kartsonis NA. 2009. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin. Infect. Dis. 48:1676-1684.
8. Cornely OA, Lasso M, Betts R, Klimko N, Vazquez J, Dobb G, Velez J, Williams-Diaz A, Lipka J, Taylor A, Sable C, Kartsonis N. 2007. Caspofungin for the treatment of less common forms of invasive candidiasis. J. Antimicrob. Chemother. 60:363-369.
9. Maertens J, Glasmacher A, Herbrecht R, Thiebaut A, Cordonnier C, Segal BH, Killar J, Taylor A, Kartsonis N, Patterson TF. 2006. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 107:2888-2897.
10. Migoya EM, Mistry GC, Stone JA, Comisar W, Sun P, Norcross A, Bi S, Winchell GA, Ghosh K, Uemera N, Deutsch PJ, Wagner JA. 2011. Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants. J. Clin. Pharmacol. 51:202-211.
11. Cornely OA, Vehreschild JJ, Vehreschild MJGT, Würthwein G, Arenz D, Schwartz S, Heussel CP, Silling G, Mahne M, Franklin J, Harnischmacher U, Wilkens A, Farowski F, Karthaus M, Lehrnbecher T, Ullmann AJ, Hallek M, Groll AH. 2011. A phase II dose escalation study of caspofungin for invasive aspergillosis. Antimicrob. Agents Chemother. 55:5798-5803.
12. Würthwein G, Cornely OA, Vehreschild JJ, Vehreschild MJGT, Farowski F, Hallek M, Groll AH. 2012. Population pharmacokinetics of caspofungin in a phase II dose escalation study, abstr. 2360. Abstr. 21st Population Approach Group in Europe Meeting. www.page-meeting.org/?abstr=2360.
13. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, Heussel CP, Lortholary O, Rieger C, Boehme A, Aoun M, Horst HA, Thiebaut A, Ruhnke M, Reichert D, Vianelli N, Krause SW, Olavarria E, Herbrecht R. 2007. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin. Infect. Dis. 44:1289-1297.
14. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
15. Farowski F, Cornely OA, Vehreschild JJ, Hartmann P, Bauer T, Steinbach A, Ruping MJ, Muller C. 2010. Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography- tandem mass spectrometry. Antimicrob. Agents Chemother. 54:1815-1819.
16. Jonsson EN, Karlsson MO. 1999. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58:51-64.
17. Holford NH. 1996. A size standard for pharmacokinetics. Clin. Pharmacokinet. 30:329-332.
18. Karlsson MO, Savic RM. 2007. Diagnosing model diagnostics. Clin. Pharmacol. Ther. 82:17-20.
19. Lindbom L, Pihlgren P, Jonsson N. 2005. PsN-toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Computer Methods Programs Biomed. 79:241-257.
20. Wang DD, Zhang S. 2012. Standardized visual predictive check versus visual predictive check for model evaluation. J. Clin. Pharmacol. 52: 39-54.
21. Würthwein G, Young C, Lanvers-Kaminsky C, Hempel G, Trame MN, Schwerdtfeger R, Ostermann H, Heinz WJ, Cornely OA, Kolve H, Boos J, Silling G, Groll AH. 2012. Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients. Antimicrob. Agents Chemother. 56:536-543.
22. Mehvar R. 2012. Principles of nonlinear pharmacokinetics. Am. J. Pharm. Ed. 65:178-184.
23. European Medicines Agency. 2011. Cancidas. European public assessment report (EPAR). European Medicines Agency, London, United Kingdom. Accessed 25 May 2012. http://www.emea.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/000379/WC500021033.pdf.
24. Food and Drug Administration. 2010. Caspofungin. Cancidas FDA label information. Food and Drug Administration, Rockville, MD. Accessed 1 February 2013. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/021227s031lbl. pdf.
25. Keating GM, Jarvis B. 2001. Caspofungin. Drugs 61:1121-1129.
26. Nguyen TH, Hoppe-Tichy T, Geiss HK, Rastall AC, Swoboda S, Schmidt J, Weigand MA. 2007. Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J. Antimicrob. Chemother. 60:100-106.
27. Stone EA, Fung HB, Kirschenbaum HL. 2002. Caspofungin: an echinocandin antifungal agent. Clin. Ther. 24:351-377.
28. Wagner C, Graninger W, Presterl E, Joukhadar C. 2006. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology 78:161-177.
29. Chen SC, Slavin MA, Sorrell TC. 2011. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 71:11-41.
30. van der Elst KC, Bruggemann RJ, Rodgers MG, Alffenaar JW. 2012. Plasma concentrations of caspofungin at two different dosage regimens in a patient with hepatic dysfunction. Transpl. Infect. Dis. 14:440-443.
31. Stone JA, Holland SD, Wickersham PJ, Sterrett A, Schwartz M, Bonfiglio C, Hesney M, Winchell GA, Deutsch PJ, Greenberg H, Hunt TL, Waldman SA. 2002. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother. 46:739-745.
32. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, Kim RB. 2005. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab. Dispos. 33:676-682.
33. Stone JA, Xu X, Winchell GA, Deutsch PJ, Pearson PG, Migoya EM, Mistry GC, Xi L, Miller A, Sandhu P, Singh R, DeLuna F, Dilzer SC, Lasseter KC. 2004. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob. Agents Chemother. 48:815-823.
34. Mistry GC, Migoya E, Deutsch PJ, Winchell G, Hesney M, Li S, Bi S, Dilzer S, Lasseter KC, Stone JA. 2007. Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations. J. Clin. Pharmacol. 47:951-961.
35. Stone JA, Migoya EM, Hickey L, Winchell GA, Deutsch PJ, Ghosh K, Freeman A, Bi S, Desai R, Dilzer SC, Lasseter KC, Kraft WK, Greenberg H, Waldman SA. 2004. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob. Agents Chemother. 48:4306-4314.
36. Walsh TJ, Adamson PC, Seibel NL, Flynn PM, Neely MN, Schwartz C, Shad A, Kaplan SL, Roden MM, Stone JA, Miller A, Bradshaw SK, Li SX, Sable CA, Kartsonis NA. 2005. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother. 49:4536-4545.